

Clinical observation of Drug slow release depot therapy (DRSDT) in the treatment of 288 cases diagnosed with primary liver cancer

Jing-Peng¹, Ma Zhenlu¹, Guan Changjiang¹, Gaofeng¹, Yu Baofa¹

(1) Baofa Cancer Hospital, Beijing, China

Objective

To explore the curative effect of Drug slow release depot therapy (DRSDT) for treatment of liver cancer.

Methods

To conduct DRSDT on 288 cases of liver cancer patients.

Results

According to WHO evaluation standard of curative effect for solid tumor, follow up and record the evaluation result, CE 5 cases, PR 151 cases, NC 125 cases, the total efficiency is 54.17% 3 year survival rate of stage II patients is 100%. And 1 year survival rate for stage III patients is 60.4%. After the treatment, the general condition of the patients improved, symptoms relieved, life quality improved, without serious complications.

Conclusion

DRSDT has better responses with less complications on different stages of primary liver cancer.

Keywords

Liver Cancer; Drug slow release depot therapy (DRSDT); curative effect